

## **Prematurely ended-statement**

**EudraCT Number:** 2006-006962-41

**Full title of trial:** Dendritic cells as autologous vaccine in patients with chronic myeloid leukemia

**Protocol Code:** CSTI571ADE60

**Sponsor:** Charité – Universitätsmedizin Berlin

**Sponsor Representative:** Prof. Dr. med. Jörg Westermann  
Medizinische Klinik m. . Hämatologie, Onkologie und Tumorummunologie  
Campus Virchow-Klinikum  
Augustenburger Platz 1, 13353 Berlin  
[Joerg.westermann@charite.de](mailto:Joerg.westermann@charite.de)

**Product:** autologous DC pulsed with peptides + adjuvans

**Date of the early Termination:** 30/04/2020

**Statement:** A restart of the study was not feasible due to the very high costs and work involved in commissioning a production facility for DC manufacture adapted to the new requirements and simultaneous recruitment problems, so we decided to discontinue the study. A total of 2 patients were included, with only 1 patient receiving the full treatment.